First Time Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 11 498 GBX -2.43% Market Closed
Updated: May 31, 2023

Intrinsic Value

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. [ Read More ]

The intrinsic value of one AZN stock under the Base Case scenario is 18 297.57 GBX. Compared to the current market price of 11 498 GBX, AstraZeneca PLC is Undervalued by 37%.

Key Points:
AZN Intrinsic Value
Base Case
18 297.57 GBX
Undervaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

Financials

Balance Sheet Decomposition
AstraZeneca PLC

Current Assets 22.3B
Cash & Short-Term Investments 6.5B
Receivables 10.8B
Other Current Assets 5B
Non-Current Assets 74.4B
Long-Term Investments 1.2B
PP&E 9.6B
Intangibles 59.3B
Other Non-Current Assets 4.3B
Current Liabilities 24.9B
Accounts Payable 19.2B
Short-Term Debt 568M
Other Current Liabilities 5.1B
Non-Current Liabilities 36B
Long-Term Debt 27.6B
Other Non-Current Liabilities 8.4B
Efficiency
Fundamental Scores

AZN Profitability Score
Profitability Due Diligence

AstraZeneca PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
58/100
Profitability
Score

AstraZeneca PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

AZN Solvency Score
Solvency Due Diligence

AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
46/100
Solvency
Score

AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AZN Price Targets Summary
AstraZeneca PLC

Wall Street analysts forecast AZN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AZN is 12 783.33 GBX with a low forecast of 6 185.98 GBX and a high forecast of 18 375 GBX.

Lowest
Price Target
6 185.98 GBX
46% Downside
Average
Price Target
12 783.33 GBX
11% Upside
Highest
Price Target
18 375 GBX
60% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

AZN Competitors
AstraZeneca PLC

AZN Suppliers & Customers
AstraZeneca PLC

Suppliers Map
Customers Map

Shareholder Return

AZN Return Decomposition
Main factors of price return

Market capitalization of AZN shares increased by 195.72% over the past 5 years. The primary factor behind the change was an increase in revenue growth from 22.3B to 43.8B, leading to a growth in the market capitalization of AstraZeneca PLC by 121.67%.

Market capitalization of AZN shares increased by 195.72% over the past 5 years. The primary factor behind the change was an increase in revenue growth from 22.3B to 43.8B, leading to a growth in the market capitalization of AstraZeneca PLC by 121.67%.

+195.72%
60.3B 178B
Market Cap Growth
+93.96%
27.9 47
P/E Change
+101.76%
2.7B 4.7B
Earnings Growth
Market Cap Growth
+195.72%
P/E Change
+93.96%
Earnings Growth
+101.76%
What is price return decomposition?

AZN Price
AstraZeneca PLC

1M 1M
-2%
6M 6M
+4%
1Y 1Y
+12%
3Y 3Y
+42%
5Y 5Y
+142%
10Y 10Y
+387%
Annual Price Range
11 498
52w Low
9 519.3046
52w High
12 294
Price Metrics
Average Annual Return 15.11%
Standard Deviation of Annual Returns 14.65%
Max Drawdown -6%
Shares Statistics
Market Capitalization 178B GBX
Shares Outstanding 1 549 830 016
Percentage of Shares Shorted
N/A

Company Profile

AstraZeneca PLC Logo
AstraZeneca PLC

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

178B GBP

Dividend Yield

0%

Description

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The firm is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The firm has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Contact

CAMBRIDGESHIRE
Cambridge
1 Francis Crick Avenue
+11442073045000.0
https://www.astrazeneca.com/Home

IPO

2007-09-21

Employees

83 100

Officers

CEO & Exec. Director
Mr. Pascal Soriot D.V.M., M.B.A.
CFO & Exec. Director
Dr. Aradhana Sarin M.D.
CEO of Alexion & Chief Strategy Officer
Mr. Marc Dunoyer
EVP of Operations & Information Technology and Member of External Sustainability Advisory Board
Ms. Pam P. Cheng
Head of Investor Relations
Mr. Chris Sheldon
Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board
Mr. Jeffrey Pott
Show More
EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
Ms. Katarina Ageborg
Head of Global Media Relations
Gonzalo Vina
EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
Dr. Menelas Pangalos Ph.D.
Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
Dr. Ruud Dobber Ph.D.
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one AZN stock?

The intrinsic value of one AZN stock under the Base Case scenario is 18 297.57 GBX.

Is AZN stock undervalued or overvalued?

Compared to the current market price of 11 498 GBX, AstraZeneca PLC is Undervalued by 37%.